Genentech's Gazyva approved for idiopathic nephrotic syndrome
Roche-owned Genentech has received U.S. Food and Drug Administration (FDA) approval to expand the indication of its drug Gazyva (obinutuzumab) to include treatment for idiopathic nephrotic syndrome, a rare kidney disorder marked by excessive protein in urine leading to swelling. Idiopathic nephrotic syndrome is characterized by significant edema and can be challenging to manage. The approval reflects the growing recognition of Gazyva's therapeutic potential beyond its original indications in lymphoma treatment. This new indication could broaden Genentech’s market reach, potentially increasing revenue from a drug already established in oncology settings.
Tickers: $RHHBY
Topics: drug approval pharmaceuticals